*AbbVie, InterMune say they defending business secrets. The decision leaves in limbo a high-profile fight that has pitched the European Medicines Agency, Europe's equivalent of the U.S. Food and Drug Administration, against AbbVie and InterMune.» Read More
GlaxoSmithKline profits dipped 1% in the first quarter, as sales were hit by the strength of sterling and the loss of patent protection on key medicines, Europe's biggest drugmaker said on Wednesday.
Here's our re-cap of today with the leaderboard, most active and widely held as well as the trivia questions. (we have video of all this below). The video question is worth $2,000 Bonus Bucks: According to the Alix Partners brand survey, which company was voted the least trusted brand in America? Your selection of answers is: Microsoft or Kraft or Ford or Sony.
Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.
Here's a look at the latest contest stock action. Mergers and acquisitions played a strong part in the best performers (MedImmune, Baush & Lomb) as well as earnings figures (Angiodynamics). A couple of newer names showed up in the most active list (Ligand and Angiotech) while the widely held stocks stayed the same.
A bidding war for Alliance Boots ended Tuesday with the company's deputy chairman and a private equity firm emerging the winner after a sweetened 11 billion pound ($22 billion) offer pushed a rival private equity group out of the running.
Amgen, the world's largest biotechnology company, reported higher first-quarter profit on Monday, driven by increased sales of its anemia and arthritis drugs. Excluding items, the Thousand Oaks, Calif.-based company earned $1.08 a share, matching analysts' average forecast of $1.08 a share, according to Thomson Financial.
M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.
AstraZeneca has agreed to buy U.S. biotechnology company MedImmune for more than $15 billion in the biggest transaction since the creation of the Anglo-Swedish drugs group in 1999.
Mylan Laboratories spacer said U.S. regulators approved its generic version of Sanofi-Aventis' sleeping pill, Ambien, in the 5 mg and 10 mg strengths.
In a previous blog post, I wrote about what happened at this year's American College of Cardiology conference in New Orleans when at least one doctor "leaked" the results of a major, highly anticipated study comparing drug-coated stents to old-fashioned heart drugs. The ACC had to move up the embargo time of the data by one day and reporters had to scramble to meet the hastened deadline.
Demand for a free vaccine against cervical cancer is outstripping supply in New Hampshire, which was the first state in the country to approve free distribution of the vaccine, which protects girls against four strains of a sexually transmitted infection called human papillomavirus, or HPV.
Strong sales of its flagship drugs boosted net profit at Swiss drugmaker Novartis by 11% to $2.171 billion, the group said on Monday, confounding expectations for a weaker profit.
Earnings blowouts from Google and strong guidance from two key names in the industrial sector were among the catalysts for Friday's most-active stocks.
The average markup or premium paid in a biotech M & A deal worth at least $500 million in 2006 was 60%. 60%! That's one of the most startling numbers you'll find in Ernst & Young's 21st Annual "Global Biotechnology Report".
Gardasil -- Merck's new vaccine for HPV and cervical cancer -- has been a lightning rod for social controversy since it came to market in the second half of last year. Should Merck be lobbying state's to mandate it? Should parents be forced to have their pre-adolescent, presumably pre-sexually-active kids to get it? Who will pay for it? (It costs about $400 for all three shots which are given over several months.)
Good morning. Serge Amelyan continues to hold the top position on the overall leaderboard, while the upset occurs as Parker Robinson falls to third, displaced by Vitaliy Khizder who moves into 2nd. As we said Thursday, Serge is the first contestant to break the $3M mark with a total portfolio value of $3,275,721.77 up $39,498.72 from Wednesday's total on the sale of...
Amgen fools us: One of my favorite exercises at the Breaking News Desk is to figure out whether something is news, and how it might move the stock involved. This morning, a headline moved regarding Amgen’s anemia drug Aranesp. I’m not a pharmaceutical expert -- that’s why we have reporter Mike Huckman -- but since it involved a very large company and a drug I’d actually heard of, we knew it was news. Here’s where it got interesting...
Shares of Amgen surged after the biotech giant said that its anemia drug Aranesp showed no difference in risk of death compared with a placebo in a closely watched study of the medicine in small-cell lung cancer patients.
Here's our re-cap of today--with the leaderboard, most active and widely held stocks as well as our trivia questions. We'll start there. The video question is worth $2,000 Bonus Bucks: According to this morning’s report, China’s first quarter GDP was up how much? The selection of answers are: 5.7% or 8.5% or 10.2% or 11.1%.
Wow--we've gotten posts from all three guest bloggers today as this one from Timothy Sykes wraps it up. You certainly have some food for thought. Here's Timothy: Many contestants have been asking why I advocate such a seemingly risky strategy by focusing on chart plays with upcoming earnings. The answer, like my strategy, is rather simple.